Novo Nordisk’s Hemophilia Data Offers Rare Bright Spot as Revenue Guidance Darkens
Novo Nordisk’s hemophilia A drug Denecimig shows 99% fewer bleeds in Phase 3, bolstering FDA filing as GLP-1…
Novo Nordisk’s Teen Trial Win Offers a Glimmer as US Price War Bites
Novo Nordisk’s oral semaglutide shows breakthrough in teens with type 2 diabetes, but US pricing squeeze and Eli…
Novo Nordisk’s Blood Disorder Breakthrough Offers a Lifeline Amid GLP-1 Gloom
Novo Nordisk’s etavopivat succeeds in Phase 3 sickle cell trial, cutting painful crises by 27%. This diversifies its…
LifeMD Offers Novo Nordisk’s Industry-First Wegovy® Telehealth Subscription Program
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo Nordisk…